NEULANDLAB - IntraDay Trade Analysis with Live Signals

Last Updated Time : 19 Sept 25, 2:16 pm

IntraDay Trade Rating: 4.0

🧬 Intraday Trade Analysis for NEULANDLAB

Neuland Laboratories shows a strong technical setup for intraday trading today, supported by bullish momentum, low debt, and a breakout structure. However, stretched valuation and a sharp drop in quarterly profit suggest caution on extended moves.

📊 Technical & Momentum Overview

RSI (67.1): Bullish, nearing overbought — momentum is strong but approaching saturation.

MACD (703): Strong positive crossover — confirms trend continuation.

Price Action: Trading well above 50 DMA (₹13,972) and 200 DMA (₹12,755), indicating short-term and medium-term strength.

Volume: Current volume (86.6K) is slightly below 1-week average (88.7K), showing stable but not surging intraday interest.

📈 Fundamental Snapshot

Valuation: P/E of 156 vs industry PE of 33.4 — extremely overvalued; PEG of 3.30 suggests premium pricing.

Profitability: ROCE (18.7%) and ROE (14.8%) are solid; EPS is ₹136.

Quarterly Profit: Dropped sharply from ₹27.7 Cr. to ₹13.7 Cr. — sentiment dampener.

Institutional Flow: FII holdings declined (-0.43%), DII increased (+0.60%) — mixed but net supportive.

Debt: Very low (0.10) — adds financial stability.

🎯 Optimal Buy Price for Today

Buy Zone: ₹15,800–₹15,850

Entry near support with tight stop-loss. Avoid chasing above ₹15,900 unless volume spikes and RSI remains stable.

💰 Exit Levels for Profit-Taking & Stop-Loss

Strategy Price Level (₹) Rationale

Target 1 16,050 Minor resistance zone

Target 2 16,200 Momentum extension target

Stop-Loss 15,700 Below intraday support

🕒 If You Already Hold NEULANDLAB Today

Exit on Weakness

Price drops below ₹15,700 with rising volume.

RSI dips below 64 or MACD flattens.

Exit on Strength

Price nears ₹16,050–₹16,200 with declining volume or bearish divergence.

Watch for reversal candles or lower highs on 5-min chart.

This setup favors breakout scalping with tight stops and disciplined execution. Let me know if you'd like to compare NEULANDLAB with other pharma midcaps showing similar momentum.

Edit in a page